Aytu BioPharma, Inc.
Szimbólum: AYTU
NASDAQ
2.9043
USDMai piaci árfolyam
-0.9631
P/E arány
-0.0159
PEG-arány
16.17M
MRK Cap
- 0.00%
DIV hozam
Aytu BioPharma, Inc. (AYTU) Pénzügyi kimutatások
Mérleg
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 81.66 | 23 | 19.4 | 49.6 | |||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.net-receivables | 122.27 | 28.9 | 21.7 | 28.2 | |||||||||||||||||
balance-sheet.row.inventory | 51.6 | 12 | 10.8 | 16.3 | |||||||||||||||||
balance-sheet.row.other-current-assets | 4.13 | 0.9 | 0.6 | 1 | |||||||||||||||||
balance-sheet.row.total-current-assets | 293.27 | 72.8 | 59.9 | 105.2 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 15.7 | 3.9 | 6.3 | 8.7 | |||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 65.8 | |||||||||||||||||
balance-sheet.row.intangible-assets | 235.49 | 59 | 70.6 | 85.5 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 235.49 | 59 | 70.6 | 151.3 | |||||||||||||||||
balance-sheet.row.long-term-investments | -1.38 | -1.4 | 0 | -10.9 | |||||||||||||||||
balance-sheet.row.tax-assets | 1.38 | 1.4 | 0 | 10.9 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 3.36 | 0.8 | 0.8 | 0.5 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 254.55 | 63.6 | 77.7 | 160.4 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 547.82 | 136.5 | 137.6 | 265.7 | |||||||||||||||||
balance-sheet.row.account-payables | 53.09 | 13.5 | 11 | 19.3 | |||||||||||||||||
balance-sheet.row.short-term-debt | 17.7 | 1.6 | 3.9 | 25.5 | |||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 55.92 | 14.7 | 14.3 | 2.8 | |||||||||||||||||
Deferred Revenue Non Current | -1.38 | -1.4 | 0 | -11.2 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1.38 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 82.35 | 7.1 | 49.5 | 7.4 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 118.45 | 28.1 | 27.1 | 18.7 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 4.05 | 0.8 | 2.2 | 3.6 | |||||||||||||||||
balance-sheet.row.total-liab | 402.53 | 97.1 | 91.5 | 128.1 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.retained-earnings | -1230.52 | -304.1 | -288.5 | -178.3 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1375.81 | 343.5 | 334.6 | 315.9 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | 145.29 | 39.4 | 46.1 | 137.6 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 547.82 | 136.5 | 137.6 | 265.7 | |||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-equity | 145.29 | 39.4 | 46.1 | 137.6 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 547.82 | - | - | - | |||||||||||||||||
Total Investments | -1.38 | -1.4 | 0 | -10.9 | |||||||||||||||||
balance-sheet.row.total-debt | 73.62 | 16.4 | 18.2 | 28.3 | |||||||||||||||||
balance-sheet.row.net-debt | -8.04 | -6.6 | -1.2 | -21.3 |
Cash Flow kimutatás
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -18 | -17.1 | -110.2 | -58.3 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 8.72 | 8.8 | 10.3 | 9.2 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 7.31 | 3.3 | 0 | 22.3 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 3.55 | 6 | 5.2 | 3.6 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 1.71 | -5.8 | -10.9 | 1.7 | |||||||||||||||||
cash-flows.row.account-receivables | -3.79 | -7.2 | 6.5 | 1.5 | |||||||||||||||||
cash-flows.row.inventory | -2.57 | -3.6 | 1.3 | 2.8 | |||||||||||||||||
cash-flows.row.account-payables | 0.19 | 2.4 | -7.7 | -3.2 | |||||||||||||||||
cash-flows.row.other-working-capital | 7.87 | 2.6 | -11 | 0.6 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 2.81 | -0.4 | 76.7 | -4.5 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 6.11 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | 0 | -2.3 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | -3.2 | -2.8 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-investing-activites | -0.4 | -0.1 | -0.1 | 2.4 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -0.4 | -0.1 | -3.2 | -2.8 | |||||||||||||||||
cash-flows.row.debt-repayment | -2.39 | -2.3 | -172.5 | -54.9 | |||||||||||||||||
cash-flows.row.common-stock-issued | 3.93 | 15.6 | 11.7 | 45.1 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-financing-activites | -7.22 | -4.4 | 162.3 | 40.2 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -5.68 | 8.9 | 1.5 | 30.3 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 0.03 | 3.6 | -30.5 | 1.6 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 81.66 | 23 | 19.4 | 49.9 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 81.63 | 19.4 | 49.9 | 48.3 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 6.11 | -5.1 | -28.8 | -26 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | 0 | -2.3 | |||||||||||||||||
cash-flows.row.free-cash-flow | 6.11 | -5.1 | -28.8 | -28.3 |
Eredménykimutatás sor
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 98.5 | 107.4 | 96.7 | 65.6 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 36.2 | 40.8 | 44.4 | 36.4 | |||||||||||||||||
income-statement-row.row.gross-profit | 62.29 | 66.6 | 52.3 | 29.2 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 2.45 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 25.68 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 34.78 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | -1.94 | -4.8 | 4.1 | 6 | |||||||||||||||||
income-statement-row.row.operating-expenses | 65.31 | 79 | 88.4 | 67.4 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 101.52 | 119.7 | 132.8 | 103.9 | |||||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.interest-expense | -3.86 | 0 | 147.5 | 0 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 34.78 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -11.55 | -4.7 | -147.5 | -19.8 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | -1.94 | -4.8 | 4.1 | 6 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | -11.55 | -4.7 | -147.5 | -19.8 | |||||||||||||||||
income-statement-row.row.interest-expense | -3.86 | 0 | 147.5 | 0 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 5.71 | 4.8 | 4.1 | 23.7 | |||||||||||||||||
income-statement-row.row.ebitda-caps | -0.31 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | -8.26 | -17.1 | 37.2 | -38.2 | |||||||||||||||||
income-statement-row.row.income-before-tax | -17.17 | -17.1 | -110.3 | -58 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 1.25 | -0.1 | -0.1 | 0.3 | |||||||||||||||||
income-statement-row.row.net-income | -16.64 | -17.1 | -110.2 | -58.3 |
Gyakran ismételt kérdés
Mi a Aytu BioPharma, Inc. (AYTU) az összes eszköz?
Aytu BioPharma, Inc. (AYTU) az összes eszköz 136463000.000.
Mekkora a vállalkozás éves bevétele?
Az éves bevétel 45033000.000.
Mennyi a cég haszonkulcsa?
A cég haszonkulcsa 0.632.
Mennyi a vállalat szabad cash flow-ja?
A szabad pénzáramlás 1.108.
Mi a vállalati nettó haszonkulcs?
A nettó haszonkulcs -0.169.
Mennyi a vállalat teljes bevétele?
A teljes bevétel -0.084.
Mi a Aytu BioPharma, Inc. (AYTU) nettó profit (nettó nyereség)?
A nettó nyereség (nettó bevétel) -17051000.000.
Mennyi a cég teljes adóssága?
Az összes adósság 16361000.000.
Mi a működési költségek száma?
A működési költségek 78961000.000.
Mennyi a cég készpénzállománya?
A vállalati pénzeszközök 19529000.000.